CLS vs. VRNA

Last updated Jun 9, 2026

CLS (Celestica Inc.) and VRNA (Verona Pharma plc) are both stocks. CLS operates in Electronic Components (Technology), while VRNA operates in Biotechnology (Healthcare). At a 0.17 correlation, their price movements are largely independent.

Performance

CLS vs. VRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Celestica Inc. (CLS) and Verona Pharma plc (VRNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

CLS

• 1D: 3.98%
• 1M: 2.92%
• YTD: 30.75%
• 6M: 13.42%
• 1Y: 220.14%
• 3Y*: 209.55%
• 5Y*: 114.81%
• 10Y*: 43.16%

VRNA

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

CLS vs. VRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
CLS Celestica Inc.	30.75%	220.27%	215.23%	159.80%	1.26%	37.92%	-2.42%	-5.70%	-16.32%	-27.92%
VRNA Verona Pharma plc	0.00%	130.21%	133.60%	-23.92%	288.84%	-4.00%	21.74%	-40.41%	-18.71%	-12.07%

Correlation

The correlation between CLS and VRNA is 0.06, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.06
Correlation (3Y) Calculated over the trailing 3-year period	0.24
Correlation (5Y) Calculated over the trailing 5-year period	0.21
Correlation (All Time) Calculated using the full available price history since Apr 27, 2017	0.17

The correlation between CLS and VRNA shifts across timeframes, from 0.06 (1 year) to 0.24 (3 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap CLS : $44.72B VRNA : $9.72B
EPS CLS : $8.28 VRNA : -$0.69
PS Ratio CLS : 3.24 VRNA : 57.97
PB Ratio CLS : 21.31 VRNA : 34.92
Total Revenue (TTM) CLS : $13.81B VRNA : $167.65M
Gross Profit (TTM) CLS : $1.60B VRNA : $159.52M
EBITDA (TTM) CLS : $1.32B VRNA : -$40.86M

Return for Risk

CLS vs. VRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CLS

CLS Risk / Return Rank: 93
CLS Sharpe Ratio Rank: 95
CLS Sortino Ratio Rank: 89
CLS Omega Ratio Rank: 88
CLS Calmar Ratio Rank: 96
CLS Martin Ratio Rank: 95

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CLS vs. VRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Celestica Inc. (CLS) and Verona Pharma plc (VRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CLS	VRNA	Difference
Sharpe ratio: Return per unit of total volatility	3.06	—	—
Sortino ratio: Return per unit of downside risk	2.94	—	—
Omega ratio: Gain probability vs. loss probability	1.39	—	—
Calmar ratio: Return relative to maximum drawdown	7.58	—	—
Martin ratio: Return relative to average drawdown	18.88	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	CLS	VRNA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	3.06	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	2.01	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.87	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.27	—	—

Drawdowns

Drawdown Indicators

	CLS	VRNA	Difference
Max Drawdown Largest peak-to-trough decline	-96.93%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-29.24%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-53.96%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-53.96%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-80.60%	—	—
Current Drawdown Current decline from peak	-18.18%	—	—
Average Drawdown Average peak-to-trough decline	-73.36%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	11.72%	—	—

Volatility

Volatility by Period

	CLS	VRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	26.60%	—	—
Volatility (6M) Calculated over the trailing 6-month period	55.08%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	72.52%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	57.62%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	49.93%	—	—

Dividends

CLS vs. VRNA - Dividend Comparison

Neither CLS nor VRNA has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

CLS vs. VRNA - Profitability Comparison

The chart below illustrates the profitability comparison between Celestica Inc. and Verona Pharma plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

CLS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported a gross profit of 437.20M and revenue of 4.05B. Therefore, the gross margin over that period was 10.8%.

VRNA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.

CLS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported an operating income of 272.10M and revenue of 4.05B, resulting in an operating margin of 6.7%.

VRNA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.

CLS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported a net income of 212.30M and revenue of 4.05B, resulting in a net margin of 5.3%.

VRNA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.

Frequently Asked Questions

Can I hold both CLS and VRNA in my portfolio?

CLS and VRNA have a correlation of 0.06, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.